Neurofilaments and tau proteins in cerebrospinal fluid and serum in dementias and neuroinflammation.
暂无分享,去创建一个
[1] K. Blennow,et al. Subcortical Vascular Dementia Biomarker Pattern in Mild Cognitive Impairment , 2009, Dementia and Geriatric Cognitive Disorders.
[2] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[3] Henrik Zetterberg,et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa , 2016, Clinical chemistry and laboratory medicine.
[4] Xiongwei Zhu,et al. Neurofilamentopathy in Neurodegenerative Diseases , 2011, The open neurology journal.
[5] W. M. van der Flier,et al. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes , 2015, Alzheimer's & dementia.
[6] M N Rossor,et al. A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia , 2007, Neurodegenerative Diseases.
[7] H. Zetterberg. Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments , 2015, Current opinion in psychiatry.
[8] B. Mollenhauer,et al. Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD , 2015, Journal of Neurology.
[9] P. Kaňovský,et al. Cerebrospinal fluid levels of chromogranin A and phosphorylated neurofilament heavy chain are elevated in amyotrophic lateral sclerosis , 2017, Acta neurologica Scandinavica.
[10] N. Mattsson. CSF biomarkers in neurodegenerative diseases , 2011, Clinical chemistry and laboratory medicine.
[11] J. Fleming,et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking , 2009, Neurology.
[12] John R Hodges,et al. The Addenbrooke's Cognitive Examination Revised (ACE‐R): a brief cognitive test battery for dementia screening , 2006, International journal of geriatric psychiatry.
[13] James C. Vickers,et al. Defining the Earliest Pathological Changes of Alzheimer’s Disease , 2016, Current Alzheimer research.
[14] J. Morrison,et al. Alterations in neurofilament protein immunoreactivity in human hippocampal neurons related to normal aging and Alzheimer's disease , 1994, Neuroscience.
[15] P. Scheltens,et al. Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers , 2012, Neurobiology of Aging.
[16] L. Kurlowicz,et al. The Mini Mental State Examination (MMSE). , 1999, Director.
[17] Alzheimer's Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease , 2017 .
[18] Henrik Zetterberg,et al. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease , 2017, JAMA neurology.
[19] R. Lindberg,et al. Neurofilament heavy chain and heat shock protein 70 as markers of seizure‐related brain injury , 2012, Epilepsia.
[20] P. Adlard,et al. The cause of neuronal degeneration in Alzheimer's disease , 2000, Progress in Neurobiology.
[21] D. Schöttle,et al. The Neurofilament Heavy Chain (NfHSMI35) in the Cerebrospinal Fluid Diagnosis of Alzheimer’s Disease , 2006, Dementia and Geriatric Cognitive Disorders.
[22] M. Strong,et al. Post-transcriptional control of neurofilaments: New roles in development, regeneration and neurodegenerative disease , 2010, Trends in Neurosciences.
[23] K. Blennow,et al. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. , 2014, JAMA neurology.
[24] P. Scheltens,et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[25] K. Blennow,et al. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD , 2000, Neurology.
[26] I. Dujmovic. Cerebrospinal Fluid and Blood Biomarkers of Neuroaxonal Damage in Multiple Sclerosis , 2011, Multiple sclerosis international.
[27] B. Hemmer,et al. EFNS guidelines on disease‐specific CSF investigations , 2009, European journal of neurology.
[28] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[29] D. Řípová,et al. Structure and Pathology of Tau Protein in Alzheimer Disease , 2012, International journal of Alzheimer's disease.
[30] H. Pant,et al. Direct evidence of phosphorylated neuronal intermediate filament proteins in neurofibrillary tangles (NFTs): phosphoproteomics of Alzheimer's NFTs , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[31] W. M. van der Flier,et al. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis , 2011, Clinical chemistry and laboratory medicine.
[32] Y. Pijnenburg,et al. CSF neurofilament proteins in the differential diagnosis of dementia , 2007, Journal of Neurology, Neurosurgery & Psychiatry.
[33] E. Janousová,et al. Addenbrookský kognitivní test – orientační normy pro českou populaci Addenbrooke ’ s Cognitive Examination – Approximate Normal Values for the Czech Population , 2019 .
[34] K. Blennow,et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival , 2014, Neurology.
[35] P. Scheltens,et al. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe , 2010, European journal of neurology.
[36] A. Bartoš,et al. The Mini-Mental State Examination: Czech Norms and Cutoffs for Mild Dementia and Mild Cognitive Impairment due to Alzheimer's Disease , 2016, Dementia and Geriatric Cognitive Disorders.
[37] L. Hagberg,et al. Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction , 2000, Journal of Neurology.
[38] Ludwig Kappos,et al. Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases , 2013, PloS one.
[39] R. Perrot,et al. Neuronal intermediate filaments and neurodegenerative disorders , 2009, Brain Research Bulletin.
[40] A. Bartoš,et al. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis , 2013, Journal of Neuroimmunology.
[41] Henrik Zetterberg,et al. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. , 2016, JAMA neurology.
[42] M. Costa,et al. The neurofilament triplet is present in distinct subpopulations of neurons in the central nervous system of the guinea-pig , 1992, Neuroscience.
[43] P. Scheltens,et al. CSF Neurofilaments in Frontotemporal Dementia Compared with Early Onset Alzheimer’s Disease and Controls , 2007, Dementia and Geriatric Cognitive Disorders.
[44] Hang Su,et al. Plasma neurofilament light chain levels in Alzheimer’s disease , 2017, Neuroscience Letters.
[45] William T. Hu,et al. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. , 2014, JAMA neurology.